Basit öğe kaydını göster

Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC).

dc.contributor.authorAntonia, Scott Joseph
dc.contributor.authorQuantin, Xavier
dc.contributor.authorHui, Rina
dc.contributor.authorOzguroglu, Mustafa
dc.contributor.authorMurakami, Shuji
dc.contributor.authorBroadhurst, Helen
dc.contributor.authorNewton, Michael
dc.contributor.authorDennis, Phillip A.
dc.contributor.authorNaidoo, Jarushka
dc.contributor.authorVansteenkiste, Johan F.
dc.contributor.authorFaivre-Finn, Corinne
dc.date.accessioned2021-03-03T13:18:52Z
dc.date.available2021-03-03T13:18:52Z
dc.date.issued2020
dc.identifier.citationNaidoo J., Vansteenkiste J. F. , Faivre-Finn C., Ozguroglu M., Murakami S., Hui R., Quantin X., Broadhurst H., Newton M., Dennis P. A. , et al., "Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC).", JOURNAL OF CLINICAL ONCOLOGY, cilt.38, sa.15, 2020
dc.identifier.issn0732-183X
dc.identifier.othervv_1032021
dc.identifier.otherav_334e3a25-11e8-4944-86b4-21592f30c7e7
dc.identifier.urihttp://hdl.handle.net/20.500.12627/38768
dc.language.isoeng
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.titleNon-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC).
dc.typeMakale
dc.relation.journalJOURNAL OF CLINICAL ONCOLOGY
dc.contributor.department, ,
dc.identifier.volume38
dc.identifier.issue15
dc.contributor.firstauthorID2281409


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster